Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 461-465

  Kumagai, Hozumi ^a   Kusaba, Hitoshi ^a   Okumura, Yuta ^a   Komoda, Masato ^a   Nakano, Michitaka ^a   Tamura, Shingo ^a   Uchida, Mayako ^a   Nagata, Kenichiro ^a   Arita, Shuji ^a,b   Ariyama, Hiroshi ^a   Takaishi, Shigeo ^c   Akashi, Koichi ^a   Baba, Eishi ^b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Dexamethasone; Fosaprepitant; Highly emetogenic chemotherapy

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZIMIDAZOLE DERIVATIVE; DEXAMETHASONE; FOSAPREPITANT; GRANISETRON; ISOQUINOLINE DERIVATIVE; MORPHOLINE DERIVATIVE; PALONOSETRON; QUINUCLIDINE DERIVATIVE; RAMOSETRON; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; HUMAN; JAPAN; MALE; MIDDLE AGED; NEOPLASM; RETROSPECTIVE STUDY; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; ISOQUINOLINES; JAPAN; MALE; MIDDLE AGED; MORPHOLINES; NEOPLASMS; QUINUCLIDINES; RETROSPECTIVE STUDIES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 84894032707     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.461     Document Type: Article

References (12)

1. Aapro MS, Grunberg SM, Manikhas GM, et al (2006). A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol, 17, 1441-9.
2. del Giglio A, Soares HP, Caparroz C, Castro PC (2000). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting-Results of a meta-analysis of randomized controlled trials. Cancer, 89, 2301-8.
3. F. Roila, J. Herrstedt, M. Aapro, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43.
4. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C (1998). Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study. Ann Oncol, 9, 661-6.
5. Grunberg S, Chua D, Maru A, et al (2011). Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE. J Clin Oncol, 29, 1495-501.
6. Hale JJ, Mills SG, MacCoss M, et al (2000). Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem, 43, 1234-41.
7. Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin The Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9.
8. Italian Group for Antiemetic Research (1998). Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol, 16, 2937-42.
9. John PA. Ioannidis, Paul JH, Joseph L (2000). Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol, 18, 3409-22.
10. Kris MG, Gralla RJ, Tyson LB, et al (1989). Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol, 7, 108-14.
11. McCrea JB, Majumdar AK, Goldberg MR, et al (2003). Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 74, 17-24.
12. Saito H, Yoshizawa H, Yoshimori K, et al (2013). Effificacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol, 24, 1067-73.